Kong Xiaofeng, Yao Fei, Chen Jibing et al.
[Abstract]
Objective To investigate combined pereutaneous and endbronchial cryotherapy therapy for the treatment of central type lung cancer(CTLC)．
Methods Forty-seven patients with unrespectable CTLC can be divided into 3 parts，22 cases of endotraeheal tumors，26 cases of tracheal wall tumors and 21 cases of extratraeheal type tumors．Sixty nine times of combined percutaneous cryosurgery，endobronchial cryosurgery and airway stenting were carried out in these patients．The progression-free survivals(PFS)of enrolled patients were assessed and the influence of tumor location，pathologic type and differentiation to PFS were discussed later．
Result Within 3 days after treatment，ventilatory capacity and performance status had obviously increased and cough，signs of dyspnea，hemoptysis and atelectasis improved significantly，but symptoms of pneumothorax and pleural effusion emerged．After 2 weeks，all complications had disappeared completely．PFS for endotraeheal tumors(8±4 months)Was shorter than that for tracheal wall(1 3．4-6 months，P<0．05)and extratraeheal(14 4-8 months，P<0．01)tumors．The PFS ofNSCLC(11±5 months)Was significantly longer than that of SCLC(4±2 months，P<0．0001)．PFS of medium or well differentiated CTLC(15±8 months) Was significantly longer than that of poorly differentiated CTLC(7±3 months，P<0．0001)．
Conclusion In conclusion，combined eryotherapy is a safe and effective treatment for CTLC．PFS can be influenced by tumor location and pathologic type．
[Key words] Central type lung cancer；Percutaneous cryosurgery； Airway stenting；Endobronchial Cryosurgery
